Bicara Therapeutics (BCAX) Total Liabilities (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Total Liabilities data on file, last reported at $39.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 107.33% year-over-year to $39.6 million; the trailing twelve-month figure through Mar 2026 stood at $39.6 million (up 107.33% YoY), and the FY2025 full-year result was $29.5 million, up 63.03% from the prior year.
• Total Liabilities for Q1 2026 stood at $39.6 million, up from $29.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $174.8 million in Q2 2024 and bottomed at $14.6 million in Q3 2024.
• The 4-year median for Total Liabilities is $21.9 million (2025), against an average of $59.0 million.
• The widest annual swing landed in 2025, when Total Liabilities sank 89.48%; it then surged 107.33% in 2026.
• A 4-year view of Total Liabilities shows it stood at $15.5 million in 2023, then grew by 17.11% to $18.1 million in 2024, then soared by 63.03% to $29.5 million in 2025, then soared by 34.19% to $39.6 million in 2026.
• The last three Total Liabilities figures came in at $39.6 million (Q1 2026), $29.5 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.

Peer Comparison